Laryngeal Cancer Therapeutics Market Report and Forecast 2025-2034

Published Jul 28, 2025

Length 350 Pages

SKU # EMAR20319922

Description

The laryngeal cancer therapeutics market size in the 7 major regions was valued at USD 4.10 Billion in 2024, driven by the increasing incidence of laryngeal cancer across these regions. The market size is anticipated to grow at a CAGR of 4.20% during the forecast period of 2025-2034 to achieve a value of USD 6.19 Billion by 2034.

Laryngeal Cancer Therapeutics: Introduction

Laryngeal cancer, which affects the voice box or larynx, presents symptoms that can often be mistaken for other conditions, making early diagnosis crucial. The most common sign is persistent hoarseness, sometimes misconstrued as a common cold symptom. If you notice ongoing symptoms such as a sore throat, chronic cough, voice changes lasting beyond two weeks, swallowing difficulties, a lump in the neck or throat, trouble producing voice sounds (dysphonia), or ear pain, it is essential to consult a healthcare provider for a proper diagnosis. Treatment for laryngeal cancer may involve surgical procedures like laryngectomy, which entails the removal of part or all the larynx. The risk of developing laryngeal cancer is significantly elevated by smoking or using tobacco products.

Laryngeal Cancer Therapeutics Market Analysis

Significant advancements and investments in the field are significantly propelling the laryngeal cancer therapeutics market demand. One significant trend in the market is the increased investment activities. For example, an investment of over USD 11 million by the California Institute for Regenerative Medicine (CIRM) to support a phase II clinical trial aimed at testing a cell therapy for aiding throat cancer patients in their recovery from the adverse effects of radiation therapy has taken place recently. This promising initiative is conducted by Professor Peter Belafsky, an expert in otolaryngology, who also directs the UC Davis Health Center for Voice and Swallowing.

Additionally, innovative technologies are emerging to enhance the diagnosis and treatment of laryngeal cancer further influencing the laryngeal cancer therapeutics market growth. For example, a team of students, led by a lecturer in the Department of Physics at William & Mary, is developing an advanced instrument called Britescope, designed to improve endotracheal intubation procedures. Britescope's potential for success and life-saving capabilities have garnered support from the Virginia Innovation Partnership Corporation's Commonwealth Commercialization Fund. These investments and technological innovations are driving positive trends in the laryngeal cancer therapeutics market, offering new hope for patients and improving treatment outcomes.

Laryngeal Cancer Therapeutics Market Segmentations

“laryngeal cancer therapeutics market and forecast 2025-2034” offers a detailed analysis of the market based on the following segments:

Market Breakup by Product Type

Biologics
Small Molecules

Market Breakup by Treatment Type

Radiation Therapy
Chemotherapy
Immunotherapy
Others

Market Breakup by Route of Administration

Oral
Parenteral
Topical

Market Breakup by Stage

Stage 0
Stage-I
Stage-II
Stage-III
Stage-IV

Market Breakup by End User

Hospitals
Homecare
Specialty Centres
Others

Market Breakup by Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Market Breakup by Region

United States
EU-4 and the United Kingdom

Germany

France

Italy

Spain

United Kingdom

Japan

Laryngeal Cancer Therapeutics Market Overview

The market is witnessing significant growth driven by several key factors. For example, according to the latest estimates from the American Cancer Society, there are expected to be about 12,380 new cases of laryngeal cancer in the United States in 2023, indicating a rising prevalence of neck and head cancers. This surge in cases is fuelling the demand for combination therapies to effectively treat these cancers expected to contribute to the market growth.

Moreover, substantial growth in research and development activities aimed at developing innovative cancer therapeutics is also contributing to the laryngeal cancer therapeutics market growth. The increasing adoption of head and neck cancer therapeutics is also acting as a major driver, which is propelled by the urgent need for more effective treatments.

North America is currently leading the regional market due to the high number of head and neck cancers in the region. Regional market players are actively engaging in product launches, mergers, and acquisitions to establish a significant presence in the market to further boost market growth. Additionally, the presence of well-developed healthcare infrastructure and the active involvement of various government organizations in addressing the mounting burden of head and neck cancer are further propelling the regional market growth.

Laryngeal Cancer Therapeutics Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

Johnson & Johnson Private Limited
Cipla Inc.
Abbott
AbbVie Inc.
Merck KGaA
Bausch Health Companies Inc.
Sun Pharmaceutical Industries Ltd.
Aurobindo Pharma
Lupin
Hikma Pharmaceuticals PLC
Amneal Pharmaceuticals LLC.
Pfizer Inc.
Mylan N.V.
Bristol-Myers Squibb Company
GSK plc.

*Please Note:* The report will take 5 business days to complete, after order confirmation.

1 Preface: 1.1 Objectives of the Study; 1.1 Key Assumptions; 1.2 Report Coverage – Key Segmentation and Scope; 1.3 Research Methodology
2 Executive Summary
3 Laryngeal Cancer Overview: 3.1 Guidelines and Stages; 3.2 Pathophysiology; 3.3 Screening and Diagnosis; 3.4 Treatment Pathway
4 Patient Profile: 4.1 Patient Profile Overview; 4.2 Patient Psychology and Emotional Impact Factors; 4.3 Risk Assessment and Treatment Success Rate
5 Laryngeal Cancer Therapeutics Epidemiology Analysis-7MM: 5.1 7MM Epidemiology Scenario Overview (2018-2034); 5.2 United States Laryngeal Cancer Epidemiology Forecast (2018-2034); 5.3 EU-4 and United Kingdom Laryngeal Cancer Epidemiology Forecast (2018-2034); 5.3.1 Germany Laryngeal Cancer Epidemiology Forecast (2018-2034); 5.3.2 France Laryngeal Cancer Epidemiology Forecast (2018-2034); 5.3.3 Italy Laryngeal Cancer Epidemiology Forecast (2018-2034); 5.3.4 Spain Laryngeal Cancer Epidemiology Forecast (2018-2034); 5.3.5 United Kingdom Laryngeal Cancer Epidemiology Forecast (2018-2034); 5.4 Japan Laryngeal Cancer Epidemiology Forecast (2018-2034)
6 Laryngeal Cancer Treatment Market Overview – 7MM: 6.1 Laryngeal Cancer Treatment Market Historical Value (2018-2024); 6.2 Laryngeal Cancer Treatment Market Forecast Value (2025-2034)
7 Laryngeal Cancer Therapeutics Market Landscape: 7.1 Laryngeal Cancer Therapeutics: Developers Landscape; 7.1.1 Analysis by Year of Establishment; 7.1.2 Analysis by Company Size; 7.1.3 Analysis by Region; 7.2 Laryngeal Cancer Therapeutics: Product Landscape; 7.2.1 Analysis by Product Type; 7.2.2 Analysis by Treatment Type; 7.2.3 Analysis by Route of Administration
8 Laryngeal Cancer Therapeutics Challenges and Unmet Needs: 8.1 Treatment Pathway Challenges; 8.2 Compliance and Drop-Out Analysis; 8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Laryngeal Cancer Therapeutics Market Dynamics: 10.1 Market Drivers and Constraints; 10.2 SWOT Analysis; 10.3 Porter’s Five Forces Model; 10.4 Key Demand Indicators; 10.5 Key Price Indicators; 10.6 Industry Events, Initiatives, and Trends; 10.7 Value Chain Analysis
11 Laryngeal Cancer Therapeutics Market Segmentation-7MM: 11.1 Laryngeal Cancer Therapeutics Market by Product Type; 11.1.1 Market Overview; 11.1.2 Biologics; 11.1.3 Small Molecules; 11.2 Laryngeal Cancer Therapeutics Market by Treatment Type; 11.2.1 Market Overview; 11.2.2 Radiation Therapy; 11.2.3 Chemotherapy; 11.2.4 Immunotherapy; 11.2.5 Others; 11.3 Laryngeal Cancer Therapeutics Market by Route of Administration; 11.3.1 Market Overview; 11.3.2 Oral; 11.3.3 Parenteral; 11.3.4 Topical; 11.4 Laryngeal Cancer Therapeutics Market by Stage; 11.4.1 Market Overview; 11.4.2 Stage 0; 11.4.3 Stage-I; 11.4.4 Stage-II; 11.4.5 Stage-III; 11.4.6 Stage-IV; 11.5 Laryngeal Cancer Therapeutics Market by End User; 11.5.1 Market Overview; 11.5.2 Hospitals; 11.5.3 Homecare; 11.5.4 Specialty Centres; 11.5.5 Others; 11.6 Laryngeal Cancer Therapeutics Market by Distribution Channel; 11.6.1 Market Overview; 11.6.2 Hospital Pharmacies; 11.6.3 Retail Pharmacies; 11.6.4 Online Pharmacies; 11.7 Laryngeal Cancer Therapeutics Market by Region; 11.7.1 Market Overview; 11.7.2 United States; 11.7.3 EU-4 and the United Kingdom; 11.7.4 Japan
12 United States Laryngeal Cancer Therapeutics Market: 12.1 U.S. Laryngeal Cancer Therapeutics Market Historical Size (2018-2024); 12.2 U.S. Laryngeal Cancer Therapeutics Market Forecast Size (2025-2034); 12.3 Market Size by Therapeutic Class
13 EU-5 and the United Kingdom Laryngeal Cancer Therapeutics Market: 13.1 EU-5 and the United Kingdom Laryngeal Cancer Therapeutics Market Historical Size (2018-2024); 13.2 EU-5 and the United Kingdom Laryngeal Cancer Therapeutics Market Forecast Size (2025-2034); 13.3 Market Size by Therapeutic Class
14 Japan Laryngeal Cancer Therapeutics Market: 14.1 Japan Laryngeal Cancer Therapeutics Market Historical Size (2018-2024); 14.2 Japan Laryngeal Cancer Therapeutics Market Forecast Size (2025-2034); 14.3 Market Size by Therapeutic Class
15 Regulatory Framework: 15.1 Regulatory Overview; 15.1.1 US FDA; 15.1.2 EU EMA; 15.1.3 JAPAN PMDA
16 Patent Analysis: 16.1 Analysis by Type of Patent; 16.2 Analysis by Publication year; 16.3 Analysis by Issuing Authority; 16.4 Analysis by Patent Age; 16.5 Analysis by CPC Analysis; 16.6 Analysis by Patent Valuation; 16.7 Analysis by Key Players
17 Grants Analysis: 17.1 Analysis by year; 17.2 Analysis by Amount Awarded; 17.3 Analysis by Issuing Authority; 17.4 Analysis by Grant Application; 17.5 Analysis by Funding Institute; 17.6 Analysis by NIH Departments; 17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis: 18.1 Analysis by Trial Registration Year; 18.2 Analysis by Trial Status; 18.3 Analysis by Trial Phase; 18.4 Analysis by Therapeutic Area; 18.5 Analysis by Geography
19 Funding and Investment Analysis: 19.1 Analysis by Funding Instances; 19.2 Analysis by Type of Funding; 19.3 Analysis by Funding Amount; 19.4 Analysis by Leading Players; 19.5 Analysis by Leading Investors; 19.6 Analysis by Geography
20 Partnership and Collaborations Analysis: 20.1 Analysis by Partnership Instances; 20.2 Analysis by Type of Partnership; 20.3 Analysis by Leading Players; 20.4 Analysis by Geography
21 Supplier Landscape: 21.1 Johnson & Johnson Private Limited; 21.1.1 Financial Analysis; 21.1.2 Product Portfolio; 21.1.3 Demographic Reach and Achievements; 21.1.4 Mergers and Acquisitions; 21.1.5 Certifications; 21.2 Cipla Inc.; 21.2.1 Financial Analysis; 21.2.2 Product Portfolio; 21.2.3 Demographic Reach and Achievements; 21.2.4 Mergers and Acquisitions; 21.2.5 Certifications; 21.3 Abbott; 21.3.1 Financial Analysis; 21.3.2 Product Portfolio; 21.3.3 Demographic Reach and Achievements; 21.3.4 Mergers and Acquisitions; 21.3.5 Certifications; 21.4 AbbVie Inc.; 21.4.1 Financial Analysis; 21.4.2 Product Portfolio; 21.4.3 Demographic Reach and Achievements; 21.4.4 Mergers and Acquisitions; 21.4.5 Certifications; 21.5 Merck KGaA; 21.5.1 Financial Analysis; 21.5.2 Product Portfolio; 21.5.3 Demographic Reach and Achievements; 21.5.4 Mergers and Acquisitions; 21.5.5 Certifications; 21.6 Bausch Health Companies Inc.; 21.6.1 Financial Analysis; 21.6.2 Product Portfolio; 21.6.3 Demographic Reach and Achievements; 21.6.4 Mergers and Acquisitions; 21.6.5 Certifications; 21.7 Sun Pharmaceutical Industries Ltd.; 21.7.1 Financial Analysis; 21.7.2 Product Portfolio; 21.7.3 Demographic Reach and Achievements; 21.7.4 Mergers and Acquisitions; 21.7.5 Certifications; 21.8 Aurobindo Pharma; 21.8.1 Financial Analysis; 21.8.2 Product Portfolio; 21.8.3 Demographic Reach and Achievements; 21.8.4 Mergers and Acquisitions; 21.8.5 Certifications; 21.9 Lupin; 21.9.1 Financial Analysis; 21.9.2 Product Portfolio; 21.9.3 Demographic Reach and Achievements; 21.9.4 Mergers and Acquisitions; 21.9.5 Certifications; 21.10 Hikma Pharmaceuticals PLC; 21.10.1 Financial Analysis; 21.10.2 Product Portfolio; 21.10.3 Demographic Reach and Achievements; 21.10.4 Mergers and Acquisitions; 21.10.5 Certifications; 21.11 Amneal Pharmaceuticals LLC.; 21.11.1 Financial Analysis; 21.11.2 Product Portfolio; 21.11.3 Demographic Reach and Achievements; 21.11.4 Mergers and Acquisitions; 21.11.5 Certifications; 21.12 Pfizer Inc.; 21.12.1 Financial Analysis; 21.12.2 Product Portfolio; 21.12.3 Demographic Reach and Achievements; 21.12.4 Mergers and Acquisitions; 21.12.5 Certifications; 21.13 Mylan N.V.; 21.13.1 Financial Analysis; 21.13.2 Product Portfolio; 21.13.3 Demographic Reach and Achievements; 21.13.4 Mergers and Acquisitions; 21.13.5 Certifications; 21.14 Bristol-Myers Squibb Company; 21.14.1 Financial Analysis; 21.14.2 Product Portfolio; 21.14.3 Demographic Reach and Achievements; 21.14.4 Mergers and Acquisitions; 21.14.5 Certifications; 21.15 GSK plc.; 21.15.1 Financial Analysis; 21.15.2 Product Portfolio; 21.15.3 Demographic Reach and Achievements; 21.15.4 Mergers and Acquisitions; 21.15.5 Certifications
22 Laryngeal Cancer Therapeutics - Distribution Model (Additional Insight): 22.1 Overview; 22.2 Potential Distributors; 22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight): 24.1 Very Small Companies; 24.2 Small Companies; 24.3 Mid-Sized Companies; 24.4 Large Companies; 24.5 Very Large Companies
25 Payment Methods (Additional Insight): 25.1 Government Funded; 25.2 Private Insurance; 25.3 Out-of-Pocket

Pricing

Currency Rates

Single User Email from Publisher $4,949
Global Site License Email from Publisher $6,969

How Do Licenses Work?

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

Chat Now